These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34061209)

  • 21. Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.
    Zhang DZ; Wei XD; Wang XP
    World J Gastroenterol; 2015 Apr; 21(15):4635-43. PubMed ID: 25914473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late gadolinium enhancement of colorectal liver metastases post-chemotherapy is associated with tumour fibrosis and overall survival post-hepatectomy.
    Cheung HMC; Karanicolas PJ; Hsieh E; Coburn N; Maraj T; Kim JK; Elhakim H; Haider MA; Law C; Milot L
    Eur Radiol; 2018 Aug; 28(8):3505-3512. PubMed ID: 29476216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed tumour enhancement on gadoxetate-enhanced MRI is associated with overall survival in patients with colorectal liver metastases.
    Cheung HMC; Karanicolas PJ; Coburn N; Seth V; Law C; Milot L
    Eur Radiol; 2019 Feb; 29(2):1032-1038. PubMed ID: 29992388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization.
    Luo Y; Ameli S; Pandey A; Khoshpouri P; Ghasabeh MA; Pandey P; Li Z; Hu D; Kamel IR
    Eur Radiol; 2019 Nov; 29(11):5804-5812. PubMed ID: 31073860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fat-free muscle area measured by magnetic resonance imaging predicts overall survival of patients undergoing radioembolization of colorectal cancer liver metastases.
    Faron A; Pieper CC; Schmeel FC; Sprinkart AM; Kuetting DLR; Fimmers R; Trebicka J; Schild HH; Meyer C; Thomas D; Luetkens JA
    Eur Radiol; 2019 Sep; 29(9):4709-4717. PubMed ID: 30689036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma.
    Corona-Villalobos CP; Halappa VG; Bonekamp S; Eng J; Reyes D; Cosgrove D; Rastegar N; Pan L; Pawlik TM; Kamel IR
    Invest Radiol; 2015 Apr; 50(4):283-9. PubMed ID: 25396692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT.
    Schernthaner RE; Haroun RR; Duran R; Lee H; Sahu S; Sohn JH; Chapiro J; Zhao Y; Gorodetski B; Fleckenstein F; Smolka S; Radaelli A; van der Bom IM; Lin M; Geschwind JF
    Cardiovasc Intervent Radiol; 2016 Oct; 39(10):1429-37. PubMed ID: 27380872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
    Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
    Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.
    Savic LJ; Chapiro J; Funai E; Bousabarah K; Schobert IT; Isufi E; Geschwind JH; Stark S; He P; Rudek MA; Perez Lozada JC; Ayyagari R; Pollak J; Schlachter T
    Eur Radiol; 2021 May; 31(5):3002-3014. PubMed ID: 33063185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of total tumor volume reduction ratio in initially unresectable colorectal liver metastases after first-line systemic treatment.
    He J; Li W; Zhou J; Sun H; Zhou C; Liu Y; Quan T; Fan W; Pan Z; Lin J; Peng J
    Eur J Radiol; 2023 Aug; 165():110950. PubMed ID: 37437437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI; Hsu CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Chiang JH; Lee PC; Lee SD
    BMC Gastroenterol; 2010 Dec; 10():146. PubMed ID: 21194431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.
    Abajian A; Murali N; Savic LJ; Laage-Gaupp FM; Nezami N; Duncan JS; Schlachter T; Lin M; Geschwind JF; Chapiro J
    J Vasc Interv Radiol; 2018 Jun; 29(6):850-857.e1. PubMed ID: 29548875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Ho SY; Liu PH; Hsu CY; Ko CC; Huang YH; Su CW; Lee RC; Tsai PH; Hou MC; Huo TI
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3196-3203. PubMed ID: 34159651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transarterial chemoembolization of unresectable systemic chemotherapy refractory liver metastases: a retrospective single-center analysis.
    Ren Y; Chen L; Huang S; Zhou C; Liu J; Shi Q; Yang C; Chen R; Zheng C; Han P; Xiong B
    Abdom Radiol (NY); 2020 Sep; 45(9):2862-2870. PubMed ID: 32468211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
    Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation.
    Tegel BR; Huber S; Savic LJ; Lin M; Gebauer B; Pollak J; Chapiro J
    Acta Radiol; 2020 Dec; 61(12):1708-1716. PubMed ID: 32216452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.
    Bonekamp D; Bonekamp S; Halappa VG; Geschwind JF; Eng J; Corona-Villalobos CP; Pawlik TM; Kamel IR
    Eur J Radiol; 2014 Mar; 83(3):487-96. PubMed ID: 24387824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
    Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.
    Lee JW; Yun M; Cho A; Han KH; Kim DY; Lee SM; Lee JD
    Ann Nucl Med; 2015 Jun; 29(5):400-8. PubMed ID: 25652647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.